Cannabis Use Disorder Rates Rise Sharply, Experts Reject Prohibition

Disorder Prevalence Climbs as Legal Markets Expand

Cannabis use disorder diagnoses have increased alongside the expansion of legal adult-use markets, though causation remains contested. Epidemiological surveys show a measurable uptick in individuals meeting DSM-5 criteria for cannabis use disorder—defined by tolerance, withdrawal, unsuccessful quit attempts, and impairment of daily function. The rise correlates temporally with state-level legalization, but researchers caution that improved screening, reduced stigma, and higher potency products all contribute to the observed trend.

Potency is a recurring variable. THC concentrations in flower, concentrates, and edibles have climbed steadily since 2010, with some vape cartridges now exceeding 90% THC. That's a far cry from the 3-5% THC flower common in the 1990s. Higher potency shortens the path to tolerance and dependence for a subset of users, particularly daily consumers and those who begin use before age 25.

Still, the disorder affects a minority. Prevalence estimates range from 9% to 30% of regular users, depending on study design and population sampled. Most adult consumers don't meet clinical thresholds.

Experts Advocate Harm Reduction, Not Criminalization

Public health researchers uniformly reject prohibition as a remedy, pointing to decades of evidence that criminalization worsens health outcomes. Prohibition doesn't reduce use. It drives consumption underground, eliminates quality control, and funnels users away from clinical care. Arrest and incarceration disrupt employment, housing, and family stability, compounding the harms associated with problematic use.

Harm reduction frameworks—education, potency labeling, dosage guidance, and accessible treatment—offer a path that addresses disorder without criminalizing consumers.

Several jurisdictions are piloting interventions. Vermont now requires potency disclosure on all packaging, while Colorado funds a statewide helpline and outpatient counseling network. Oregon's Measure 110 model, though politically embattled, expanded access to voluntary treatment without criminal penalties. Early data from these programs show modest uptake but no evidence that legal access itself drives disorder at population scale.

Treatment infrastructure remains the bottleneck. Most states lack licensed cannabis counselors, and insurance reimbursement for cannabis use disorder is inconsistent. That gap leaves many individuals without a covered care pathway.

What Operators and Policymakers Should Watch

Operators face growing pressure to adopt responsible-vendor protocols, including staff training, dosage guidance, and refusal-of-sale policies for visibly impaired customers. Some MSOs are piloting point-of-sale prompts that flag high-frequency purchases or unusually large basket sizes, though privacy concerns limit adoption. Budtender training now includes recognizing signs of dependence and offering referral resources.

Policymakers are weighing potency caps and taxation structures that discourage concentrate consumption. Washington State legislators proposed a 37% excise tax on products above 35% THC, though the bill stalled in committee. Potency caps poll poorly with consumers and face industry opposition. The debate isn't going away.

For background on this evolving issue, see the CannIntel topic hub on Cannabis Use Disorder.

The next signal: watch for NIH-funded longitudinal studies tracking disorder prevalence in cohorts that began use post-legalization. Those datasets will clarify whether legal markets are causative or simply correlated with rising diagnoses, and the policy conversation hinges on that distinction.